04.11.2021 07:59:54
|
Novartis To Sell 53.3 Mln Roche Shares To Roche For $20.7 Bln
(RTTNews) - Swiss drug major Novartis (NVS) has agreed to sell 53.3 million Roche bearer shares to Roche for a total consideration of $20.7 billion.
Novartis said it has been a shareholder of Roche since May, 2001 and currently holds 53.3 million bearer shares of Roche's common stock, representing approximately 33% of aggregate outstanding bearer shares. Novartis had acquired the stake between 2001 and 2003 for a total consideration of approximately $5 billion.
Novartis said Thursday it does not consider the financial investment in Roche as part of its core business and therefore not a strategic asset.
Novartis noted that it will report a gain from the sale of the stake in income from associated companies of approximately $14 billion, which will be core adjusted.
The transaction is subject to the approval by the shareholders of Roche, at the Extraordinary General Meeting of Shareholders of Roche to be held on November 26, 2021.
Meanwhile, Roche confirmed the outlook for the full year and expects a mid-single-digit sales growth at constant exchange rates. Core earnings per share growth at constant exchange rates is targeted to be broadly in line with sales growth. In addition, Roche aims at increasing the dividend in Swiss francs also for 2021.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGShmehr Nachrichten
05.02.25 |
Roche-Aktie im Plus: FDA gibt Roche-Mittel Susvimo frei (Dow Jones) | |
26.11.24 |
Roche-Aktie tiefer: Übernahme von Poseida Therapeutics - Primäres Studienziel bei Lungenkrebs-Kombitherapie verfehlt (Dow Jones) | |
21.10.24 |
Roche-Aktie im Minus: Roche meldet US-Zulassung für Begleitdiagnostikum bei Magenkrebs (dpa-AFX) | |
11.10.24 |
Roche-Aktie verliert: FDA genehmigt Roche-Medikament Itovebi zur Behandlung von Brustkrebs (Dow Jones) | |
16.09.24 |
Roche-Tochter Genentech: Erfolgreiche Zulassung einer neuen MS-Behandlung in den USA (Dow Jones) | |
27.08.24 |
Roche-Aktie verliert trotz EU-Zulassung für neues Blutkrankheitsmittel leicht (Dow Jones) |
Analysen zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGShmehr Analysen
Aktien in diesem Artikel
Novartis AG (Spons. ADRS) | 101,50 | -0,49% |
|
Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh | 38,84 | 0,20% |
|